Shares of Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE – Get Rating) have earned a consensus rating of “Hold” from the six analysts that are currently covering the company, MarketBeat.com reports. Five research analysts have rated the stock with a hold rating. The average 1-year target price among analysts that have updated their coverage on the stock in […]
Read the latest stock market news on MarketBeat. Get real-time analyst ratings, dividend information, earnings results, financials, headlines, insider trades and options data for any stock.
Lifesci Capital cut shares of Aeglea BioTherapeutics (NASDAQ:AGLE – Get Rating) from an outperform rating to a market perform rating in a research report sent to investors on Wednesday morning, MarketBeat reports. A number of other research analysts have also issued reports on the company. HC Wainwright reissued a neutral rating and issued a $1.00 […]
A number of research firms have changed their ratings and price targets for Aeglea BioTherapeutics (NASDAQ: AGLE): 4/12/2023 – Aeglea BioTherapeutics was downgraded by analysts at Lifesci Capital from an “outperform” rating to a “market perform” rating. 4/12/2023 – Aeglea BioTherapeutics had its “hold” rating reaffirmed by analysts at Jonestrading. 4/12/2023 – Aeglea BioTherapeutics was […]
Shares of Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE – Get Rating) have been given a consensus recommendation of “Hold” by the six ratings firms that are currently covering the company, Marketbeat reports. Three research analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average twelve-month price […]